According to the research report, the global melanoma therapeutics market size is expected to touch USD 14.59 Billion by 2032, from USD 5.5 Billion in 2022, growing with a significant CAGR of 10.3% from 2023 to 2032.
Key Takeaways
- North America led the global market with the highest market share of 41% in 2022.
- Asia-Pacific is expected to expand at the largest CAGR of 11.6% between 2023 and 2032.
- By Product, the immunotherapy segment has held the highest market share of 55% in 2022.
- By Product, the targeted therapy segment is anticipated to grow at a fastest CAGR of 11.7% from 2023 to 2032.
- By Drug Type, the branded drugs segment had the major market share of 91% in 2022.
- By Drug Type, the generic drug segment is projected to expand at the fastest CAGR over the projected period.
The melanoma therapeutics report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global melanoma therapeutics in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global melanoma therapeutics market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global melanoma therapeutics during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/3401
This study covers a detailed segmentation of the global melanoma therapeutics market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global melanoma therapeutics market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Johnson & Johnson Private Limited (U.S.)
- Mylan N.V. (U.S.)
- Sun Pharmaceutical Industries Limited (India)
- Sanofi S.A. ( France)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AbbVie Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Amgen Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Novartis AG (Switzerland)
- Genentech, Inc (U.S.)
- AstraZeneca (U.K.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- AB Science (France)
- AgonOX (U.S.)
- Eisai Co., Ltd (Japan)
- Pfizer, Inc. (U.S.)
Market Segmentation
By Product
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
By Drug Type
- Branded Drugs
- Generic Drugs
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global melanoma therapeutics report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global melanoma therapeutics market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Melanoma Therapeutics Market
5.1. COVID-19 Landscape: Melanoma Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Melanoma Therapeutics Market, By Product
8.1. Melanoma Therapeutics Market Revenue and Volume, by Product, 2023-2032
8.1.1. Chemotherapy
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Immunotherapy
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Targeted Therapy
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Radiation Therapy
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Melanoma Therapeutics Market, By Drug Type
9.1. Melanoma Therapeutics Market Revenue and Volume, by Drug Type, 2023-2032
9.1.1. Branded Drugs
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Generic Drugs
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Melanoma Therapeutics Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.1.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.1.3.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.1.4.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.2.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.2.3.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.2.4.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.2.5.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.2.6.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.3.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.3.3.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.3.4.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.3.5.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.3.6.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.4.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.4.3.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.4.4.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.4.5.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.4.6.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.5.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.5.3.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Product (2020-2032)
10.5.4.2. Market Revenue and Volume Forecast, by Drug Type (2020-2032)
Chapter 11. Company Profiles
11.1. Johnson & Johnson Private Limited (U.S.)
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Mylan N.V. (U.S.)
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Sun Pharmaceutical Industries Limited (India)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Sanofi S.A. (France)
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Bayer AG (Germany)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Lilly (U.S.)
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Merck & Co., Inc. (U.S.)
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. GSK plc (U.K.)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novartis AG (Switzerland)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. AbbVie Inc. (U.S.)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments